Novartis Q4 Results
Content
Click below to navigate
through the document
We continue to focus on material environmental, social and governance
factors alongside our pursuit of sustainable shareholder value creation
↓
↑
Company overview
Financial review
Conclusions
Appendix
References
Value creation
Innovation and
access to medicines
Future-proof pipeline
addressing unmet need
Broad access
to medicines
Risk mitigation
Human
Capital
Environmental
Ethical
Sustainability
Standards
Enablers
Diversity, Equity
Climate
Ethics
& Inclusion
Water
Compliance
Culture
Governance,
transparency,
non-financial
reporting
Waste
Human rights
Right thing to do
Creating sustainable social and economic impact
ATMI - Access to Medicines Index. 1. Pharmaceuticals subindustry group. Copyright Morningstar Sustainalytics. All rights reserved.
□ NOVARTIS | Reimagining Medicine.
IMPACT
Consistent
industry-leading
performance across
priority ESG ratings
#1 in Sustainalytics1
Leaders group in MSCI
Industry leader group in ISS ESG
Leadership group in ATMI
AA in CDP climate and water
៩០៩០
Novartis Q4 Results | January 31, 2024
23View entire presentation